Vera Days Of Inventory On Hand from 2010 to 2024
| VERA Stock | USD 49.75 0.92 1.88% |
Days Of Inventory On Hand | First Reported 2010-12-31 | Previous Quarter 617.74 | Current Value 549.1 | Quarterly Volatility 38.47858022 |
Check Vera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vera Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 3.8 M or Interest Income of 7.3 M, as well as many indicators such as Price To Sales Ratio of 282, Dividend Yield of 0.0 or PTB Ratio of 6.78. Vera financial statements analysis is a perfect complement when working with Vera Therapeutics Valuation or Volatility modules.
Vera | Days Of Inventory On Hand |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out the analysis of Vera Therapeutics Correlation against competitors. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.